How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease

Arlene V Drack; Jean Bennett; Stephen Russell; Katherine A High; Zi-fan Yu; Amy Tillman; Daniel Chung; Kathleen Z Reape; Thomas Ciulla; Albert Maguire

doi:10.1016/j.jaapos.2019.08.018

Abstract

How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease

Arlene V Drack, Jean Bennett, Stephen Russell, Katherine A High, Zi-fan Yu, Amy Tillman, Daniel Chung, Kathleen Z Reape, Thomas Ciulla and Albert Maguire

Journal of AAPOS, Vol.23(4), pp.e7-e7

08/2019

DOI: 10.1016/j.jaapos.2019.08.018

View Online

Details

Title: Subtitle: How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease
Creators: Arlene V Drack
Jean Bennett
Stephen Russell
Katherine A High
Zi-fan Yu
Amy Tillman
Daniel Chung
Kathleen Z Reape
Thomas Ciulla
Albert Maguire
Resource Type: Abstract
Publication Details: Journal of AAPOS, Vol.23(4), pp.e7-e7
DOI: 10.1016/j.jaapos.2019.08.018
ISSN: 1091-8531
eISSN: 1528-3933
Language: English
Date published: 08/2019
Academic Unit: Stead Family Department of Pediatrics; Ophthalmology and Visual Sciences
Record Identifier: 9984180934602771

Metrics

21 Record Views